Andersen Stine Linding, Olsen Jørn, Carlé Allan, Laurberg Peter
Departments of Endocrinology (S.L.A., A.C., P.L.) and Clinical Biochemistry (S.L.A.), Aalborg University Hospital, 9000 Aalborg, Denmark; Department of Clinical Medicine (S.L.A., P.L.), Aalborg University, 9000 Aalborg, Denmark; Section for Epidemiology, Department of Public Health (J.O.), Aarhus University, 8000 Aarhus, Denmark; and Department of Internal Medicine (A.C.), Silkeborg Hospital, 8600 Silkeborg, Denmark.
J Clin Endocrinol Metab. 2015 Mar;100(3):1164-71. doi: 10.1210/jc.2014-3588. Epub 2014 Dec 8.
Hyperthyroidism in women of reproductive age is predominantly caused by Graves' disease. Pregnancy associated changes in the immune system may influence the onset of disease, but population-based incidence rates in and around pregnancy have not been reported.
The objective of the study was to estimate the incidence of maternal hyperthyroidism (defined by redeemed prescription of antithyroid drugs) in and around pregnancy and to compare this with the incidence of other autoimmune diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).
This was a population-based cohort study.
The study used the Danish nationwide registers.
The participants were women who gave birth to singleton liveborn children in Denmark from 1999 to 2008 (n = 403,958).
MAIN OUTCOME MEASURE(S): Incidence rates (IR) of maternal hyperthyroidism during a 4-year period beginning 2 years before and ending 2 years after the date when the mother was giving birth for the first time in the study period were measured.
Altogether 3673 women (0.9%) were identified with an onset of hyperthyroidism from 1997 to 2010, and the overall IR of maternal hyperthyroidism was 65.0/100,000/year. The IR of hyperthyroidism in and around pregnancy varied widely and was high in the first 3 months of pregnancy [incidence rate ratio (IRR) vs the remaining study period: 1.50 (95% CI 1.09-2.06)), very low in the last 3 months of pregnancy (0.26 (0.15-0.44)], and reached the highest level 7-9 months postpartum [3.80 (2.88-5.02)]. The incidence variation in and around pregnancy was different for RA and IBD.
These are the first population-based data on the incidence of hyperthyroidism in and around pregnancy. The incidence of hyperthyroidism was high in early pregnancy and postpartum, whereas such particular pattern was not observed for other diseases of autoimmune origin.
育龄女性甲状腺功能亢进主要由格雷夫斯病引起。孕期免疫系统的相关变化可能会影响疾病的发病,但尚未有基于人群的孕期及孕期前后发病率的报道。
本研究旨在估算孕期及孕期前后母体甲状腺功能亢进(通过抗甲状腺药物处方量来定义)的发病率,并将其与其他自身免疫性疾病(如类风湿性关节炎(RA)和炎症性肠病(IBD))的发病率进行比较。
这是一项基于人群的队列研究。
本研究使用丹麦全国性登记数据。
研究对象为1999年至2008年在丹麦生育单胎活产婴儿的女性(n = 403,958)。
测量母亲在研究期间首次分娩日期前2年开始至产后2年结束的4年期间母体甲状腺功能亢进的发病率(IR)。
1997年至2010年期间,共识别出3673名甲状腺功能亢进发病女性(0.9%),母体甲状腺功能亢进的总体发病率为65.0/100,000/年。孕期及孕期前后甲状腺功能亢进的发病率差异很大,在妊娠前3个月较高[发病率比(IRR)与其余研究期相比:1.50(95%CI 1.09 - 2.06)],在妊娠最后3个月非常低(0.26(0.15 - 0.44)),并在产后7 - 9个月达到最高水平[3.80(2.88 - 5.02)]。RA和IBD在孕期及孕期前后的发病率变化不同。
这些是关于孕期及孕期前后甲状腺功能亢进发病率的首批基于人群的数据。甲状腺功能亢进的发病率在妊娠早期和产后较高,而自身免疫性起源的其他疾病未观察到这种特定模式。